ResearchMoz

Humalog (Type 2 Diabetes) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2012-01-31
No. Of Pages » 44


GlobalDatas pharmaceuticals report, Humalog (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Humalog sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Humalog including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Humalog including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Humalog in each of the seven major markets
Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17
5 Evolution of Anti-Diabetic Treatments 18

6 Medications 20
6.1 Insulin 20
6.2 Oral Medications 20
6.2.1 Sulfonylureas (SUR) 20
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 22
6.2.4 Meglitinides 22
6.2.5 Thiazolidinediones (TZDs) 23
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 24
6.2.7 Oral Combination Therapy 24
6.3 Other Injectionable Medications 25
6.3.1 Pramlintide 25
6.3.2 Exenatide 25
6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Humalog (insulin lispro) 26
7.1 Introduction 26
7.2 Mechanism of Action 26
7.3 Clinical Studies 26
7.3.1 Safety & Efficacy Study in Humalog & Humulin R 26
7.3.2 Comparison of Means of Glycemic Parameters 27
7.3.3 Combination Therapy 27
7.4 Approval History of Humalog 28
7.5 Factors Affecting Sales of Humalog 28
7.5.1 Growing Insulin Market 28
7.5.2 First in Class 28
7.5.3 Advantage of Humalog over Regular Insulin 28
7.5.4 Prevention of Spiking Blood Sugar between Meals 28
7.5.5 Effective Treatment for Low Blood Sugar at Night 28
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Estimates 30
7.7.1 Target Patient Pool for Humalog 30
7.7.2 Dosing 30
7.7.3 Market Penetration 31
7.7.4 Annual Cost of Therapy 31
7.7.5 Sales Projections of Humalog 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 42
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Number of patients approved to take the drug 42
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.4 Drug Sales Estimates Model 43
8.5 Contact Us 43
8.6 Disclaimer 44
8.7 Sources 44

List of Tables


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 19
Table 9: Type 2 Diabetes Mellitus Adults 26
Table 10: Comparison of Means of Glycemic Parameters at the end of Combined Treatment periods (3 months for each treatment) 27
Table 11: Results of a Two Month Study in which Humalog was added to Sulfonylurea therapy in Patients not adequately controlled on Sulfonylureas alone 27
Table 12: Approval of Humalog 28
Table 13: Drug Risk Benefit Score, Humalog 29
Table 14: Drug Risk Benefit Score, Humalog Mix 75/25 29
Table 15: Humalog, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 16: Humalog Mix 75/25, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 17: Humalog franchise, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 31
Table 18: Humalog, Type 2 Diabetes, Global, Sales Estimates ($m), 20022020 32
Table 19: Humalog, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Table 20: Humalog, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Table 21: Humalog, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Table 22: Humalog, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Table 23: Humalog, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Table 24: Humalog, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Table 25: Humalog, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022020 39

List of Figures


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylureas 20
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 21
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 22
Figure 9: Mechanism of Action of Thiazolidinediones 23
Figure 10: Mechanism of Action of DPP IV Inhibitors 24
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 25
Figure 12: Humalog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2020 32
Figure 13: Humalog, Type 2 Diabetes, The US, Sales Estimates ($m), 20022020 33
Figure 14: Humalog, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022020 34
Figure 15: Humalog, Type 2 Diabetes, France, Sales Estimates ($m), 20022020 35
Figure 16: Humalog, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022020 36
Figure 17: Humalog, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022020 37
Figure 18: Humalog, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022020 38
Figure 19: Humalog, Type 2 Diabetes, Japan, Sales Estimates ($m), 2002-2020 39
Figure 20: Humalog, Type 2 Diabetes, Sales Distribution by Country (%), 2020 40
Figure 21: Patients Approved for the Drug 43

Upcoming Reports:

Bio-Based PET Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Polyethylene terephthalate (PET) is primarily used is packaging applications of food and beverages. It is used to package water, soft drinks, alcoholic beverages, and food among others. The demand for PET has been surging at a robust growth rate of more than 9%, with its estimated global annual demand of more than 50 million tons per year. However as polyethylene terephthalate is a downstream derivative of crude oil, the market is susceptible to the price volatility of crude oil. Moreover, the growing public consciousness coupled with environmental sustainability factors has led to the...
Ketone Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Ketones usually simple are compounds that contain a carbonyl group, and due to exclusion of reactive groups such as –Cl or –OH, ketones are considered simple in nature. Industrial solvent acetone and sugar (ketoses) are some of the commonly used ketones. Various methods are implemented for the production of ketones in academic laboratories on an industrial scale, and are also produced in certain ways by organisms. Ketones are manufactured in industries on a large scale as pharmaceuticals, polymer precursors and solvents. On the basis of their type, ketones are divided into...
Portable Medical Electronic Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The portable medical electronic industry is witnessing significant growth and adoption in recent years. Mobilization of medical devices has driven the healthcare industry as the use of medical equipments has expanded beyond hospitals to homecare environments. Due to the presence of microprocessors the devices manufactured are more portable, compact and are light in weight. Rapid technological advancements in semiconductors provide large scale integration and reduced power consumption. Portable medical equipments comprises of various features such as analog front-ends for data...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

OnePlus One ready to launch it smart phone in India
Jul 28, 2014  
Chinese smart phones are gaining popularity in the Indian market. OnePlus, a Chinese smart phones company, is ready to launch the invitation-only One smart phone in India.  Many Chinese smart phone brands have got inspired by the success of another smart phone brand called Xiaomi which had successfully launched the Mi 3, a smart phone in the Indian market. The OnePlus One is a typical...
Danone all set to sell its business to Hospira
Jul 28, 2014  
According to the Financial Times, Danone, a French dairy group is aiming at selling its business pertaining to medical nutrition to Hospira, a US group. The deal value is estimated at $ 5 billion.  The plan is still in the pipeline as nothing with respect to the business is fully confirmed or certain. Representatives of neither business groups were willing to comment on the same. ...
Loss recorded due to heavy investments carried out by Amazon
Jul 25, 2014  
Amazon.com Inc has been investing in newer businesses like consumer electronics and digital content, due to which it has been running into losses for some time now. The loss recorded in the second quarter was by far the highest. In 2014, the stock prices have dropped by 10% with reduced investor confidence in the long term growth investments. The shares of this US based online retailer...
LG Electronics To Invest Huge Capital in R&D Project in South Korea
Jul 25, 2014  
LG Electronics Inc will invest USD 1.26 billion in the construction of a new research and development unit in South Korea’s capital city Seoul. The facility is said to be part of LG’s Science Park project. The 170,000 square meters site will be built in Magok, Seoul and work is expected to begin from August. Once the construction is complete and ready by 2020, the park will house...
Russian Consumer Protection Agency Seeks ban on Some McDonalds Products
Jul 25, 2014  
A lawsuit has been filed in a Moscow court by the Russian consumer protection agency to seek ban on some products from McDonald's Corp's burgers menu, along with its ice creams and shakes menu.  A regional branch of the agency has recently filed a lawsuit asking the court to declare a ban on some products due to some inappropriateness in physical-chemical parameters in the...